Patents by Inventor Craig Stivala
Craig Stivala has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240336625Abstract: Described herein are sulfonimidamide compounds, solvates thereof, tautomers thereof, and pharmaceutically acceptable salts of the foregoing. Further described herein are methods of treating a disorder in a subject in need thereof using said compounds, solvates, tautomers, or pharmaceutically acceptable salts thereof, such as NLRP3-mediated disorders.Type: ApplicationFiled: July 15, 2022Publication date: October 10, 2024Applicant: Genentech, Inc.Inventors: Kwong Wah LAI, Christian NILEWSKI, Richard M. PASTOR, Craig STIVALA
-
Publication number: 20240300974Abstract: The invention provides novel compounds having the general formula I: wherein R1, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and methods of using the compounds.Type: ApplicationFiled: November 21, 2023Publication date: September 12, 2024Applicant: Genentech, Inc.Inventors: Snahel PATEL, Gregory HAMILTON, Guiling ZHAO, Huifen CHEN, Blake DANIELS, Craig STIVALA
-
Patent number: 11834461Abstract: The invention provides novel compounds having the general formula I: wherein R1, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and methods of using the compounds.Type: GrantFiled: January 12, 2021Date of Patent: December 5, 2023Assignee: Genentech, Inc.Inventors: Snahel Patel, Gregory Hamilton, Guiling Zhao, Huifen Chen, Blake Daniels, Craig Stivala
-
Patent number: 11673892Abstract: The invention provides novel compounds having the general formula I: or pharmaceutically acceptable salts thereof, wherein RA, RB1, RB2, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and methods of using the compounds.Type: GrantFiled: April 9, 2020Date of Patent: June 13, 2023Assignee: Genentech, Inc.Inventors: Huifen Chen, Gregory Hamilton, Snahel Patel, Guiling Zhao, Blake Daniels, Craig Stivala
-
Publication number: 20230159555Abstract: Described herein are compounds of Formula (I), Formula (I-A), and Formula (I-B), solvates thereof, tautomers thereof, and pharmaceutically acceptable salts of the foregoing, Further described herein are methods of inhibiting NLRP3 using said compounds, and methods of and compositions useful in treating NLRP3-dependent disorders.Type: ApplicationFiled: July 21, 2022Publication date: May 25, 2023Applicant: Genentech, Inc.Inventors: Paul GIBBONS, Kwong Wah LAI, Christian NILEWSKI, Richard M. PASTOR, Steven Thomas STABEN, Craig STIVALA, Bing-Yan ZHU, Huifen CHEN
-
Patent number: 11566003Abstract: Isoquinoline compounds and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.Type: GrantFiled: July 6, 2020Date of Patent: January 31, 2023Assignee: Genentech, Inc.Inventors: Bryan Chan, Joy Drobnick, Lewis Gazzard, Timothy Heffron, Jun Liang, Sushant Malhotra, Rohan Mendonca, Naomi Rajapaksa, Craig Stivala, John Tellis, Weiru Wang, BinQing Wei, Aihe Zhou, Matthew W. Cartwright, Michael Lainchbury, Emanuela Gancia, Eileen Seward, Andrew Madin, David Favor, Kin Chiu Fong, Yonghan Hu, Andrew Good
-
Patent number: 11560391Abstract: The present disclosure relates to novel sulfonylurea compounds and related compounds useful in treating a disorder responsive to modulation of cytokines such as IL-1? and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.Type: GrantFiled: January 15, 2021Date of Patent: January 24, 2023Assignee: Genentech, Inc.Inventors: Jeffrey A. Stafford, James M. Veal, Lynnie Lin Trzoss, Christopher McBride, Richard M. Pastor, Steven Thomas Staben, Craig Stivala, Matthew Volgraf
-
Publication number: 20230002391Abstract: The invention provides novel compounds having the general formula I: wherein R1, RB1, RB2, n, p, q, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and methods of using the compounds.Type: ApplicationFiled: June 6, 2021Publication date: January 5, 2023Applicant: Genentech, Inc.Inventors: Snahel Patel, Gregory Hamilton, Craig Stivala, Huifen Chen, Blake Daniels
-
Publication number: 20220370420Abstract: Spirocyclic 2,3-dihydro-7-azaindole compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the spirocyclic 2,3-dihydro-7-azaindole compounds.Type: ApplicationFiled: March 17, 2021Publication date: November 24, 2022Applicant: Genentech, Inc.Inventors: Sushant Malhotra, Craig Stivala, BinQing Wei, Bryan K. Chan, Timothy Heffron, Michael Lainchbury, Andrew Madin, Terry Aaron Panchal, Eileen Mary Seward, Toby Blench, Matthew W. Cartwright, Elsa Amandine Dechaux, Richard Elliott, Emanuela Gancia
-
Publication number: 20220348559Abstract: The invention provides novel compounds having the general formula I: wherein R1, X, Z1, L, n, the A ring, the B ring, and the C ring are as described herein, pharmaceutical compositions including the compounds and methods of using the compounds.Type: ApplicationFiled: March 10, 2021Publication date: November 3, 2022Applicant: Genentech, Inc.Inventors: Snahel PATEL, Gregory HAMILTON, Craig STIVALA, Huifen CHEN, Guiling ZHAO
-
Publication number: 20210340151Abstract: Some embodiments of the invention provide compounds having the general formula I: wherein R1, R2, R3a and R3b are as described herein, pharmaceutical compositions including the compounds, and methods of using the compounds.Type: ApplicationFiled: July 8, 2021Publication date: November 4, 2021Applicant: Genentech, Inc.Inventors: Snahel PATEL, Gregory HAMILTON, Guiling ZHAO, Huifen CHEN, Blake DANIELS, Craig STIVALA
-
Publication number: 20210277024Abstract: Naphthyridine compounds of formula (I). variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.Type: ApplicationFiled: January 22, 2021Publication date: September 9, 2021Applicant: Genentech, Inc.Inventors: Terry Kellar, Jun Liang, Sushant Malhotra, Rohan V. Mendonca, Michael Siu, Craig Stivala, John C. Tellis, BinQing Wei, Bryan K. Chan, Lewis J. Gazzard, Timothy Heffron, Graham Jones, Michael Lainchbury, Andrew Madin, Eileen Mary Seward, Matthew W. Cartwright, Emanuela Gancia, David Favor, Kin Chiu Fong, Andrew Good, Yonghan Hu
-
Publication number: 20210261568Abstract: The present disclosure relates to novel sulfonylurea compounds and related compounds useful in treating a disorder responsive to modulation of cytokines such as IL-1? and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.Type: ApplicationFiled: January 15, 2021Publication date: August 26, 2021Applicant: Genentech, Inc.Inventors: Jeffrey A. STAFFORD, James M. VEAL, Lynnie Lin TRZOSS, Christopher MCBRIDE, Richard M. PASTOR, Steven Thomas STABEN, Craig STIVALA, Matthew VOLGRAF
-
Patent number: 11098058Abstract: The invention provides novel compounds having the general formula I: wherein R1, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and methods of using the compounds.Type: GrantFiled: July 12, 2018Date of Patent: August 24, 2021Assignee: Genentech, Inc.Inventors: Snahel Patel, Gregory Hamilton, Guiling Zhao, Huifen Chen, Blake Daniels, Craig Stivala
-
Publication number: 20210253580Abstract: Isoquinoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.Type: ApplicationFiled: January 22, 2021Publication date: August 19, 2021Applicant: Genentech, Inc.Inventors: Jun Liang, Sushant Malhotra, Rohan V. Mendonca, Naomi Rajapaksa, Michael Siu, Craig Stivala, John C. Tellis, BinQing Wei, Bryan K. Chan, Joy Alison Drobnick, Lewis J. Gazzard, Timothy Heffron, Graham Jones, Michael Lainchbury, Andrew Madin, Eileen Mary Seward, Matthew W. Cartwright, Emanuela Gancia, David Favor, Kin Chiu Fong, Andrew Good, Yonghan Hu
-
Publication number: 20210253596Abstract: The present disclosure relates to novel sulfonimidamide compounds and related compounds and their use in treating a disorder responsive to modulation of cytokines such as IL-1? and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.Type: ApplicationFiled: January 15, 2021Publication date: August 19, 2021Applicant: Genentech, Inc.Inventors: Christopher MCBRIDE, Lynnie Lin TRZOSS, Amogh BOLOOR, Nadezda V. SOKOLOVA, Richard M. PASTOR, Steven Thomas STABEN, Craig STIVALA, Matthew VOLGRAF, Sarah M. BRONNER
-
Patent number: 11072617Abstract: The invention provides novel compounds having the general formula I: wherein R1, RB1, RB2, n, p, q, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and methods of using the compounds.Type: GrantFiled: October 30, 2018Date of Patent: July 27, 2021Assignee: Genentech, Inc.Inventors: Snahel Patel, Gregory Hamilton, Craig Stivala, Huifen Chen, Blake Daniels
-
Patent number: 11034692Abstract: Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.Type: GrantFiled: August 15, 2019Date of Patent: June 15, 2021Assignee: Genentech, Inc.Inventors: Bryan Chan, Blake Daniels, Joy Drobnick, Lewis Gazzard, Timothy Heffron, Malcolm Huestis, Jun Liang, Sushant Malhotra, Rohan Mendonca, Naomi Rajapaksa, Michael Siu, Craig Stivala, John Tellis, Weiru Wang, BinQing Wei, Aihe Zhou, Matthew W. Cartwright, Emanuela Gancia, Graham Jones, Michael Lainchbury, Andrew Madin, Eileen Seward, David Favor, Kin Chiu Fong, Andrew Good, Yonghan Hu, Baihua Hu, Aijun Lu
-
Publication number: 20210163417Abstract: Isoquinoline compounds and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.Type: ApplicationFiled: July 6, 2020Publication date: June 3, 2021Applicant: Genentech, Inc.Inventors: Bryan Chan, Joy Drobnick, Lewis Gazzard, Timothy Heffron, Jun Liang, Sushant Malhotra, Rohan Mendonca, Naomi Rajapaksa, Craig Stivala, John Tellis, Weiru Wang, BinQing Wei, Aihe Zhou, Matthew W. Cartwright, Michael Lainchbury, Emanuela Gancia, Eileen Seward, Andrew Madin, David Favor, Kin Chiu Fong, Yonghan Hu, Andrew Good
-
Publication number: 20210139504Abstract: The invention provides novel compounds having the general formula I: wherein R1, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and methods of using the compounds.Type: ApplicationFiled: January 12, 2021Publication date: May 13, 2021Applicant: Genentech, Inc.Inventors: Snahel PATEL, Gregory HAMILTON, Guiling ZHAO, Huifen CHEN, Blake DANIELS, Craig STIVALA
